AbZelectPRO, Achieving High-Titer Productivity & Accelerated Timelines With Enhanced Cell Line Platforms

By Brett Verstak, Blanca San Miguel, Oscar Swindley , Nathan Courtier, Kean Huedepohl, Ned Swift, Miles Wellington, Sophie Douglas, Noah Collins, Elizabeth Willows, Tania Fisher, Kalpana Wood, Tanya Knight, Beata Blaszczyk, Nicole Wakes, Rob Holgate Abzena, Babraham Research Campus, Cambridge, UK

Efficient cell line development is key to accelerating biologics programs. This platform enables rapid progression from DNA to research cell banks in as little as 10 weeks, supporting a wide range of molecule formats including antibodies, fusion proteins, and vaccines. Early material generation from stable pools allows teams to begin formulation and downstream method development sooner, helping reduce risk and compress timelines.

Advanced cloning and imaging technologies ensure clonality and productivity, while high-performing clones consistently reach titers of 6–8 g/L. Stability studies across more than 60 generations demonstrate over 97% consistency, with reproducible product quality attributes throughout. A comprehensive analytics suite—including chromatographic, electrophoretic, and cell-based methods—supports robust characterization and regulatory compliance.

For teams seeking speed, scalability, and reliability in biologics development, this approach offers a proven and integrated solution. Explore the full asset to see how this platform supports complex molecule development with confidence.